Veradigm (MDRX) Competitors

Veradigm (NASDAQ:MDRX) and Omnicell (NASDAQ:OMCL) are both small-cap health care technology companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, institutional ownership, media sentiment, profitability, analyst recommendations, risk, valuation and dividends.

Is MDRX or OMCL more profitable?

Omnicell has a net margin of 2.01% compared to Veradigm's net margin of 0.00%. Omnicell's return on equity of 4.27% beat Veradigm's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Veradigm	N/A	N/A	N/A
Omnicell	2.01%	4.27%	2.44%

Which has more risk & volatility, MDRX or OMCL?

Veradigm has a beta of 0.69, indicating that its share price is 31% less volatile than the S&P 500. Comparatively, Omnicell has a beta of 0.78, indicating that its share price is 22% less volatile than the S&P 500.

Does the media prefer MDRX or OMCL?

In the previous week, Omnicell had 15 more articles in the media than Veradigm. MarketBeat recorded 16 mentions for Omnicell and 1 mentions for Veradigm. Omnicell's average media sentiment score of 1.22 beat Veradigm's score of 0.31 indicating that Omnicell is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Veradigm	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Omnicell	9 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Do institutionals and insiders believe in MDRX or OMCL?

97.7% of Omnicell shares are owned by institutional investors. 2.3% of Veradigm shares are owned by insiders. Comparatively, 2.5% of Omnicell shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Which has preferable valuation & earnings, MDRX or OMCL?

Omnicell has lower revenue, but higher earnings than Veradigm.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Veradigm	$1.53B	0.35	N/A	N/A	N/A
Omnicell	$1.11B	1.35	$12.53M	$0.50	65.62

Do analysts prefer MDRX or OMCL?

Veradigm presently has a consensus price target of $13.00, indicating a potential upside of 165.31%. Omnicell has a consensus price target of $46.71, indicating a potential upside of 42.38%. Given Veradigm's higher possible upside, equities analysts clearly believe Veradigm is more favorable than Omnicell.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Veradigm	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Omnicell	0 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.57

Summary

Omnicell beats Veradigm on 11 of the 13 factors compared between the two stocks.